Information Provided By: 
Fly News Breaks for February 22, 2019
GBT
Feb 22, 2019 | 07:19 EDT
Guggenheim analyst Yatin Suneja initiated Global Blood Therapeutics with a Buy rating and $75 price target, stating that he is optimistic about the approval of voxelotor under the FDA's accelerated pathway. If approved, he thinks voxelotor could achieve about $1.45B in peak global sales, Suneja noted.
News For GBT From the Last 2 Days
There are no results for your query GBT
